Literature DB >> 27401913

Immune Gamma Globulin Therapeutic Indications in Immune Deficiency and Autoimmunity.

Luanna Yang1, Eveline Y Wu2, Teresa K Tarrant3.   

Abstract

Immune gamma globulin (IgG) has a long history in the treatment of both primary immune deficiency and autoimmune disorders. Disease indications continue to expand and new-generation products increase the versatility of delivery. This review encompasses a historical perspective as well as current and future implications of human immune globulin for the treatment of immune-mediated illness.

Entities:  

Keywords:  Autoimmunity; Common variable immunodeficiency; Guillain-Barré; Immune deficiency; Immune globulin; Kawasaki disease; Myositis; X-linked agammaglobulinemia

Mesh：

Substances：

Year:  2016        PMID： 27401913     DOI： 10.1007/s11882-016-0632-7

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN： 1529-7322            Impact factor:   4.806


  101 in total

Review 1.  Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura.

Authors:  Feng Jin; Joseph P Balthasar
Journal:  Hum Immunol       Date:  2005-04       Impact factor: 2.850

Review 2.  The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?

Authors:  Andrew R Crow; Alan H Lazarus
Journal:  Transfus Med Rev       Date:  2008-04

Review 3.  Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders.

Authors:  Mark Sanford
Journal:  BioDrugs       Date:  2014-08       Impact factor: 5.807

4.  Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  J R Mendell; R J Barohn; M L Freimer; J T Kissel; W King; H N Nagaraja; R Rice; W W Campbell; P D Donofrio; C E Jackson; R A Lewis; M Shy; D M Simpson; G J Parry; M H Rivner; C A Thornton; M B Bromberg; R Tandan; Y Harati; M J Giuliani
Journal:  Neurology       Date:  2001-02-27       Impact factor: 9.910

Review 5.  Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections.

Authors:  Ari J Fried; Francisco A Bonilla
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

Review 6.  The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.

Authors:  Marinos C Dalakas
Journal:  Pharmacol Ther       Date:  2004-06       Impact factor: 12.310

Review 7.  Common variable immunodeficiency: etiological and treatment issues.

Authors:  Sean Deane; Carlo Selmi; Stanley M Naguwa; Suzanne S Teuber; M Eric Gershwin
Journal:  Int Arch Allergy Immunol       Date:  2009-07-01       Impact factor: 2.749

Review 8.  Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions.

Authors:  Helen Chapel; Charlotte Cunningham-Rundles
Journal:  Br J Haematol       Date:  2009-03-30       Impact factor: 6.998

Review 9.  Guillain-Barré syndrome and variants.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2013-02-19       Impact factor: 3.806

10.  Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency.

Authors:  Paula Jane Busse; Samiya Razvi; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol       Date:  2002-06       Impact factor: 10.793
View more
  4 in total

1.  Use of FEF25-75% to Guide IgG Dosing to Protect Pulmonary Function in CVID.

Authors:  Tracy Hwangpo; Zhixin Wang; Jack Ghably; Surya P Bhatt; Xiangqin Cui; Harry W Schroeder
Journal:  J Clin Immunol       Date:  2020-01-03       Impact factor: 8.317

2.  The burden of common variable immunodeficiency disorders: a retrospective analysis of the European Society for Immunodeficiency (ESID) registry data.

Authors:  Irina Odnoletkova; Gerhard Kindle; Isabella Quinti; Bodo Grimbacher; Viviane Knerr; Benjamin Gathmann; Stephan Ehl; Nizar Mahlaoui; Philippe Van Wilder; Kris Bogaerts; Esther de Vries
Journal:  Orphanet J Rare Dis       Date:  2018-11-12       Impact factor: 4.123

Review 3.  Future of Therapy for Inborn Errors of Immunity.

Authors:  Elena Perez
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-12       Impact factor: 10.817

4.  The Improvement Effect of Different Doses of Gamma Globulin on the Disease Condition of Infants with Hemolytic Disease of Newborn and Their Effects on Immune Factors in Serum.

Authors:  Shuwen Huang; Lin Liu; Guanglei Qian; Wenxue Liu; Jialiang Wang; Ming Li; Guang Yang
Journal:  Iran J Public Health       Date:  2020-05       Impact factor: 1.429
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.